98%
921
2 minutes
20
Introduction: Pallidal deep brain stimulation (GPi-DBS) is an effective therapy for isolated dystonia, but 10-20% of patients show improvement below 25-30%. We here investigated causes of insufficient response to GPi-DBS in isolated dystonia in a cross-sectional study.
Methods: Patients with isolated dystonia at time of surgery, and <30% improvement on the Burke-Fahn-Marsden dystonia-rating-scale (BFMDRS) after ≥6 months of continuous GPi-DBS were videotaped ON and OFF stimulation, and history, preoperative videos, brain MRI, medical records, stimulation settings, stimulation system integrity, lead location, and genetic information were obtained and reviewed by an expert panel.
Results: 22 patients from 11 centres were included (8 men, 14 women; 9 generalized, 9 segmental, 3 focal, 1 bibrachial dystonia; mean (range): age 48.7 (25-72) years, disease duration 22.0 (2-40) years, DBS duration 45.5 (6-131) months). Mean BFMDRS-score was 31.7 (4-93) preoperatively and 32.3 (5-101) postoperatively. Half of the patients (n = 11) had poor lead positioning alone or in combination with other problems (combined with: other disease n = 6, functional dystonia n = 1, other problems n = 2). Other problems were disease other than isolated inherited or idiopathic dystonia (n = 5), fixed deformities (n = 2), functional dystonia (n = 3), and other causes (n = 1). Excluding patients with poor lead location from further analysis, non-isolated dystonia accounted for 45.5%, functional dystonia for 27.3%, and fixed deformities for 18.2%. In patients with true isolated dystonia, lead location was the most frequent problem.
Conclusion: After exclusion of lead placement and stimulation programming issues, non-isolated dystonia, functional dystonia and fixed deformities account for the majority of GPi-DBS failures in dystonia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.parkreldis.2017.06.023 | DOI Listing |
Heterozygous loss-of-function mutations are one established cause of isolated dystonia and hyposmia. Homozygous mutations have been reported in siblings with generalized dystonia and intellectual disability. encodes major [NM_001369387.
View Article and Find Full Text PDFNeurobiol Dis
September 2025
Inserm UMR-S 1270, Paris 75005, France; Sorbonne Université, Faculty of Sciences and Engineering, Paris 75005, France; Institut du Fer à Moulin, 17 rue du Fer à Moulin, Paris 75005, France; Sorbonne Université, Institut du Cerveau, Inserm, CNRS, AP-HP, Institut de Neurologie, Hôpital de la Salp
Isolated dystonia can be caused by loss-of-function mutations in the GNAL gene (DYT-GNAL/DYT25). This gene encodes the α subunit of the heterotrimeric G protein, which, with βγ subunits, mediates the stimulatory coupling of dopamine D1 and adenosine A2A receptors to adenylyl-cyclase. These receptors are expressed in distinct striatal projection neurons (SPNs) with complementary functions in motor behavior.
View Article and Find Full Text PDFDystonia
March 2025
Department of Neurology, Massachusetts General Hospital, Boston, MA, United States.
Background And Objectives: Dystonia is the third most common movement disorder. Motor and non-motor manifestations of dystonia may impact Health Related Quality of Life (HRQoL), with lower HRQoL scores compared to the healthy population. People with generalized dystonia report worse HRQoL scores (vs.
View Article and Find Full Text PDFMov Disord
September 2025
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
Background: Previously, we identified decreased thalamic blood flow in patients with ATP1A3 variants.
Objective: This study evaluated structural gray matter organization in rapid-onset dystonia-parkinsonism (RDP) patients compared with controls and two phenotypically overlapping movement disorders.
Methods: Structural magnetic resonance imaging data were examined for whole-brain gray matter volume (GMV) abnormalities in 17 RDP patients, 20 isolated dystonia patients, 20 Parkinson's disease (PD) patients, and 20 controls.
Laryngoscope
August 2025
Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear and Harvard Medical School, Boston, Massachusetts, USA.
Background: Laryngeal dystonia (LD) is a task-specific focal dystonia marked by involuntary spasms in the laryngeal muscles during speech production. Sodium oxybate has recently been demonstrated as a new treatment option for alcohol-responsive (EtOH+) LD patients.
Objective: The objective of this study is to evaluate the long-term use of sodium oxybate for the treatment of LD.